IQV vs. JAZZ: IQVIA vs. Jazz Pharmaceuticals Stock Comparison
How do IQVIA (IQV) and Jazz Pharmaceuticals (JAZZ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
IQVIA (IQV) and Jazz Pharmaceuticals (JAZZ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but IQV is classified in Life Sciences Tools & Services while JAZZ is classified in Pharmaceuticals.
| Profile Item | IQV | JAZZ |
|---|---|---|
| Name | IQVIA Holdings Inc. | Jazz Pharmaceuticals plc |
| Country/Region | United States | Ireland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 44.80 billion USD | 15.07 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | May 9, 2013 | June 1, 2007 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | IQV | JAZZ |
|---|---|---|
| Total Return (1Y) | 32.11% | 84.44% |
| Total Return (3Y, Annualized) | 13.15% | 27.57% |
| Total Return (5Y, Annualized) | 2.00% | 12.88% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | IQV | JAZZ |
|---|---|---|
| Volatility (1Y, Annualized) | 40.77% | 38.74% |
| Beta (5Y) | 1.14 | 0.33 |
| Max Drawdown (5Y) | -51.52% | -42.03% |
| Avg. Volume (3M) | 1.40M | 878.80K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | IQV | JAZZ |
|---|---|---|
| Sharpe Ratio (1Y) | 0.68 | 2.07 |
| Sortino Ratio (1Y) | 1.03 | 4.14 |
Profitability
ROE (TTM)
IQVIA (IQV) at 21.39% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for IQV.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.39%
- Max
- 109.18%
- IQV
- 21.39%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.05%
- Max
- 109.18%
- Q3
- 6.23%
- JAZZ
- 5.05%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
IQVIA (IQV) at 8.05% retains a top-quartile share of revenue as profit, ahead of Jazz Pharmaceuticals (JAZZ) at 4.37%, which keeps about the industry-typical share.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.05%
- Max
- 18.05%
- IQV
- 8.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.37%
- Max
- 18.05%
- Q3
- 4.78%
- JAZZ
- 4.37%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Jazz Pharmaceuticals (JAZZ) at 30.17% operates in the top operating margin quartile, ahead of IQVIA (IQV) at 13.73%, which runs around its industry’s norm.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.73%
- Max
- 83.12%
- Q3
- 14.77%
- IQV
- 13.73%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.17%
- Max
- 83.12%
- JAZZ
- 30.17%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | IQV | JAZZ |
|---|---|---|
| ROE (TTM) | 21.39% | 5.05% |
| ROA (TTM) | 5.08% | 6.92% |
| Net Margin (TTM) | 8.05% | 4.37% |
| Operating Margin (TTM) | 13.73% | 30.17% |
| Gross Margin (TTM) | 33.07% | 91.10% |
Growth
Revenue Growth
Both IQVIA (IQV) at 5.87% and Jazz Pharmaceuticals (JAZZ) at 4.88% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
IQVIA (IQV) at 4.67% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | IQV | JAZZ |
|---|---|---|
| Revenue Growth (YoY) | 5.87% | 4.88% |
| Revenue Growth (3Y CAGR) | 4.21% | 5.26% |
| EPS Growth (YoY) | 4.67% | -167.51% |
| EPS Growth (3Y CAGR) | 11.08% | -- |
Financial Strength
Current Ratio (MRQ)
Both IQVIA (IQV) at 0.83 and Jazz Pharmaceuticals (JAZZ) at 1.82 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- IQV
- 0.83
- Min
- 0.10
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JAZZ
- 1.82
- Min
- 0.10
Debt / Equity (MRQ)
Both balance sheets lean debt-heavy versus peers, but IQV is more stretched: Jazz Pharmaceuticals (JAZZ) at 1.35 sits in the higher-leverage quartile and IQVIA (IQV) at 2.40 is above its industry benchmark range.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.40
- IQV
- 2.40
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 1.42
- JAZZ
- 1.35
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | IQV | JAZZ |
|---|---|---|
| Current Ratio (MRQ) | 0.83 | 1.82 |
| Debt / Equity (MRQ) | 2.40 | 1.35 |
| Net Debt / EBITDA | 4.46 | 1.39 |
Dividends
Dividend Yield (TTM)
Neither IQVIA (IQV) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- IQV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither IQVIA (IQV) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- IQV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | IQV | JAZZ |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
IQVIA (IQV) at 33.07 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.07
- Max
- 85.34
- Q3
- 43.46
- IQV
- 33.07
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
69.46
- Max
- 85.34
- JAZZ
- 69.46
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
IQVIA (IQV) at 2.59 sits in the cheaper P/S ratio quartile while Jazz Pharmaceuticals (JAZZ) at 3.19 prices around its industry’s middle — IQV costs less per dollar of sales, though read it alongside growth and margins.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.59
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- IQV
- 2.59
- Min
- 0.01
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.19
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JAZZ
- 3.19
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Jazz Pharmaceuticals (JAZZ) at 3.59 is valued about in line with its industry on P/B ratio, while IQVIA (IQV) at 6.73 carries an above-peer premium to book — IQV is pricier on assets.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.73
- Max
- 13.53
- IQV
- 6.73
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.59
- Max
- 13.53
- Q3
- 6.54
- JAZZ
- 3.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | IQV | JAZZ |
|---|---|---|
| P/E Ratio (TTM) | 33.07 | 69.46 |
| P/S Ratio (TTM) | 2.59 | 3.19 |
| P/B Ratio (MRQ) | 6.73 | 3.59 |
| Free Cash Flow Yield (TTM) | 4.72% | 11.16% |